Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07079800Active Not Recruiting

A Temporal Variability Study of Remimazolam for General Anesthesia Induction and Maintenance

Role: lead

NCT06045364Phase 1Completed

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

Role: lead

NCT06553495Not ApplicableActive Not Recruiting

A Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy

Role: lead

NCT06041984Phase 1Unknown

Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic Polypectomy

Role: lead

All 4 trials loaded